Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

chronic myeloid leukaemia

This page shows the latest chronic myeloid leukaemia news and features for those working in and with pharma, biotech and healthcare.

FDA’s year-end approvals take annual tally to 46

FDA’s year-end approvals take annual tally to 46

Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... Patients with early (chronic) phase CML who have been taking Tasigna for three years or more and whose leukaemia has responded to

Latest news

  • Novartis' orphan drug Tasigna wins EU expanded indication Novartis' orphan drug Tasigna wins EU expanded indication

    Novartis has claimed another regulatory milestone for its chronic myeloid leukaemia (CML) drug Tasigna (nilotinib), winning approval for its use to treat children in the EU. ... The European Commission approved the drug as a first-line treatment for

  • Takeda's gamble on Ariad pays off with Alunbrig approval Takeda's gamble on Ariad pays off with Alunbrig approval

    Iclusig - approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) - has been a slow-grower, largely because of safety concerns and while it has started to gain traction it

  • Takeda agrees $5.2bn deal to buy Ariad Takeda agrees $5.2bn deal to buy Ariad

    Sale of chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) therapy Iclusig for were pegged back by safety concerns that emerged in 2013 but since then have started to gain

  • Pfizer's SMO inhibitor boosts survival in blood cancer trial Pfizer's SMO inhibitor boosts survival in blood cancer trial

    Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) to almost nine months when added to low-dose ... indications such as MDS, acute lymphoblastic

  • NICE backs BMS leukaemia drug Sprycel NICE backs BMS leukaemia drug Sprycel

    NICE backs BMS leukaemia drug Sprycel. Watchdog approves blood cancer therapy for use by NHS in England and Wales. ... Bristol-Myers Squibb's chronic myeloid leukaemia treatment Sprycel (dasatinib) has been approved for NHS use in England and Wales by

More from news
Approximately 5 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase

  • Deal Watch May 2016 Deal Watch May 2016

    In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and ... acute lymphoblastic leukaemia (ALL)] in Europe

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Research &licensing agreement. 142.5. Boston Heart Diagnostics / Eurofins Scientific. Diagnostics tests for chronic conditions including cardiovascular diseases and diabetes. ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL,

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... As for the future of Iclusig in leukaemia, Ariad is keen to roll out the drug in Europe over the next few months, while regulatory

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

  • Ariad founder Harvey Berger to retire as CEO and chairman Ariad founder Harvey Berger to retire as CEO and chairman

    Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU,

  • Hugh Cole leaves Shire for Ariad Hugh Cole leaves Shire for Ariad

    This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

  • Jonathan Dickinson joins Ariad from BMS Jonathan Dickinson joins Ariad from BMS

    Jonathan Dickinson joins Ariad from BMS. Will lead launch of chronic myeloid leukaemia treatment Iclusig. ... He joins at an important time for Ariad in Europe as it prepares to launch its chronic myeloid leukaemia treatment Iclusig (ponatinib), pending

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Quick links

Infographics

Multimedia